Go Pro
→ Gold majors have a big problem (From Golden Portfolio) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innoviva, Inc. stock logo
INVA
Innoviva
$20.90
+1.2%		$21.29
$16.52
▼
$25.15
$1.51B0.33758,068 shs885,410 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$540.06
+1.0%		$530.99
$393.61
▼
$615.00
$12.48B-0.98338,684 shs156,534 shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$17.03
+0.1%		$16.95
$13.08
▼
$21.03
$884.18M0.25558,976 shs243,260 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%-3.14%-2.50%-7.85%+6.66%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-1.22%+5.31%+6.95%+23.66%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%-0.41%+0.24%+4.23%+18.95%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Innoviva, Inc. stock logo
INVA
Innoviva
$20.90
+1.2%		$21.29
$16.52
▼
$25.15
$1.51B0.33758,068 shs885,410 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$540.06
+1.0%		$530.99
$393.61
▼
$615.00
$12.48B-0.98338,684 shs156,534 shs
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$17.03
+0.1%		$16.95
$13.08
▼
$21.03
$884.18M0.25558,976 shs243,260 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Innoviva, Inc. stock logo
INVA
Innoviva
0.00%-3.14%-2.50%-7.85%+6.66%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.00%-1.22%+5.31%+6.95%+23.66%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
0.00%-0.41%+0.24%+4.23%+18.95%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Innoviva, Inc. stock logo
INVA
Innoviva
2.50
Moderate Buy$34.7566.27% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$699.6429.55% Upside
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
2.00
Hold$19.4013.92% Upside

Current Analyst Ratings Breakdown

Latest MDGL, TBPH, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
9/7/2026
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/31/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
8/17/2026
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
8/11/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B) ➝ Hold (C+)
8/7/2026
Innoviva, Inc. stock logo
INVA
Innoviva
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$36.00 ➝ $34.00
8/7/2026
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
8/4/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$605.00
8/3/2026
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
8/3/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$964.00 ➝ $962.00
7/31/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
(Data available from 9/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Innoviva, Inc. stock logo
INVA
Innoviva
$411.33M3.67$5.09 per share4.11$15.71 per share1.33
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$1.28B9.72N/AN/A$26.54 per share20.35
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$104.31M8.48N/AN/A$5.86 per share2.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Innoviva, Inc. stock logo
INVA
Innoviva
$271.17M$4.105.109.77N/A81.19%28.03%20.19%11/4/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A97.31N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$105.89M$1.0116.8621.02N/A51.58%-0.77%-0.46%11/10/2026 (Estimated)

Latest MDGL, TBPH, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/10/2026Q2 2026
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
$0.0725-$0.11-$0.1825-$0.11$22.49 million$20.73 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Innoviva, Inc. stock logo
INVA
Innoviva
0.21
16.01
15.18
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
N/A
13.54
13.54

Institutional Ownership

CompanyInstitutional Ownership
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
99.10%

Insider Ownership

CompanyInsider Ownership
Innoviva, Inc. stock logo
INVA
Innoviva
2.01%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
7.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
15972.25 million70.79 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
Theravance Biopharma, Inc. stock logo
TBPH
Theravance Biopharma
9051.92 million47.95 millionOptionable

Recent News About These Companies

VIRGINIA RETIREMENT SYSTEMS ET Al Invests $1.07 Million in Theravance Biopharma, Inc. $TBPH
September 14 at 3:52 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-virginia-retirement-systems-et-al-invests-107-million-in-theravance-biopharma-inc-tbph-2026-09-14/
Theravance Bio (TBPH) Up 0.8% Since Last Earnings Report: Can It Continue?
September 9, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2987128/theravance-bio-tbph-up-0-8-since-last-earnings-report-can-it-continue?cid=cs-stocknewsapi-ft-realtime_blog-2987128
Theravance Biopharma (NASDAQ:TBPH) Downgraded by Zacks Research to "Hold"
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-theravance-biopharma-nasdaq-tbph-downgraded-by-zacks-research-to-hold-2026-09-09/
Theravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above Fifty Day Moving Average - Time to Sell?
September 9, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-theravance-biopharma-nasdaq-tbph-stock-price-crosses-above-fifty-day-moving-average-time-to-sell-2026-09-09/
Theravance Biopharma, Inc. $TBPH is Newtyn Management LLC's 2nd Largest Position
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-theravance-biopharma-inc-tbph-is-newtyn-management-llcs-2nd-largest-position-2026-08-31/
Bank of America Corp DE Raises Position in Theravance Biopharma, Inc. $TBPH
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-bank-of-america-corp-de-raises-position-in-theravance-biopharma-inc-tbph-2026-08-31/
Theravance Biopharma, Inc. (NASDAQ:TBPH) Short Interest Update
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-theravance-biopharma-inc-nasdaq-tbph-short-interest-update-2026-08-28/
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Rating of "Hold" by Analysts
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-theravance-biopharma-inc-nasdaq-tbph-given-consensus-rating-of-hold-by-analysts-2026-08-28/
Theravance Biopharma Inc
August 20, 2026  |  money.usnews.comhttps://money.usnews.com/investing/stocks/tbph-theravance-biopharma-inc/vitals
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
August 15, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260815466380/en/tbph-stock-alert-halper-sadeh-llc-is-investigating-whether-theravance-biopharma-inc.-is-obtaining-a-fair-price-for-its-shareholders/
Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH
August 15, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-wedge-capital-management-l-l-p-nc-buys-shares-of-128845-theravance-biopharma-inc-tbph-2026-08-15/
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks
August 11, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2972612/tbph-meets-q2-earnings-estimates-to-be-acquired-by-zymeworks?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2972612
Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 10, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/theravance-biopharma-inc-reports-second-quarter-2026-financial-results-and-provides-corporate-update-302847090.html
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 6, 2026  |  financialpost.comF
Theravance Biopharma Stock Dividends | NASDAQ:TBPH | Benzinga
July 13, 2026  |  benzinga.comhttps://www.benzinga.com/quote/TBPH/dividends
Theravance Biopharma (NASDAQ:TBPH) Major Shareholder Sells $428,712.51 in Stock
July 2, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-tbph-insider-buying-and-selling-2026-07-02/
Theravance Stock Down 3% After Zymeworks Announces Buyout
June 30, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2945126/theravance-stock-down-3-after-zymeworks-announces-buyout?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-2945126
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Theravance Biopharma, Inc. (NASDAQ: TBPH)
June 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/hareholder-alert-the-ma-class-action-firm-announces-an-investigation-of-theravance-biopharma-inc-nasdaq-tbph-302813398.html
TBPH Stock Alert: Halper Sadeh LLC is Investigating Whether Theravance Biopharma, Inc. is Obtaining a Fair Price for its Shareholders
June 29, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260629457557/en/tbph-stock-alert-halper-sadeh-llc-is-investigating-whether-theravance-biopharma-inc.-is-obtaining-a-fair-price-for-its-shareholders/
Shareholder Alert: Ademi LLP investigates whether Theravance Biopharma, Inc. is obtaining a Fair Price for Public Shareholders
June 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/shareholder-alert-ademi-llp-investigates-whether-theravance-biopharma-inc-is-obtaining-a-fair-price-for-public-shareholders-302813144.html
Theravance Biopharma, Inc.: Theravance Biopharma Enters Into Definitive Agreement To Be Acquired By Zymeworks For $17.00 Per Share In Cash Plus A Contingent Value Right
June 29, 2026  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2026-06/68889854-theravance-biopharma-inc-theravance-biopharma-enters-into-definitive-agreement-to-be-acquired-by-zymeworks-for-dollar-17-00-per-share-in-cash-plus-a-cont-008.htm

New MarketBeat Followers Over Time

Media Sentiment Over Time

Innoviva stock logo

Innoviva NASDAQ:INVA

$20.90 +0.24 (+1.16%)
Closing price 04:00 PM Eastern
Extended Trading
$20.90 0.00 (-0.02%)
As of 06:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$540.06 +5.57 (+1.04%)
Closing price 04:00 PM Eastern
Extended Trading
$539.59 -0.47 (-0.09%)
As of 05:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Theravance Biopharma stock logo

Theravance Biopharma NASDAQ:TBPH

$17.03 +0.02 (+0.12%)
Closing price 04:00 PM Eastern
Extended Trading
$17.04 +0.00 (+0.03%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas